Liu Yu-Chen, Yin Cheng-Liang, Chen Qi, Chen Jing, Ma Yan-Qing, Wang Li-Li, Liu Dai-Hong, Shi Jin-Long, Dou Li-Ping
Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China,The Hospital of PLA Unit 66058, Tianjin 301799, China.
Medical Big Data Center, Chinese PLA General Hospital, Beijing 100853, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Apr;28(2):377-384. doi: 10.19746/j.cnki.issn.1009-2137.2020.02.004.
To investigate the clinical and prognostic value of SLC25A12 in patients with acute myeloid leukemia (AML).
The expression levels of SLC25A12 in bone marrow or peripheral blood cells of AML patients and healthy people in two independent cohorts (n=46, n=290, respectively) were compared. Then it was assessed that the prognostic value of SLC25A12 expression in two independent AML study cohorts (n=163, n=329, respectively) by mean of integrated analysis of genomic, transcriptome, clinical and prognosis information.
The expression of SLC25A12 in AML patients significantly increased as compared with that of healthy people (P=0.0001, P=0.0238, respectively). Univariate and multivariate analyze showed that high SLC25A12 expression was significantly associated with shorter event-free survival (EFS)(HR=1.605, P=0.018) and overall survival (OS)(HR=1.818, P=0.002) of patients. In favorable-risk and intermediate-risk subgroups, patients with high SLC25A12 expression showed shorter EFS and OS than patients with low SLC25A12 expression.
High SLC25A12 expression significantly associated with poor prognosis of AML patients, which suggests that SLC25A12 aberrant expression can be used as a potential molecular marker for prognosis evaluation of AML patients.
探讨溶质载体家族25成员12（SLC25A12）在急性髓系白血病（AML）患者中的临床及预后价值。
比较两个独立队列中AML患者和健康人骨髓或外周血细胞中SLC25A12的表达水平（分别为n = 46和n = 290）。然后通过整合基因组、转录组、临床和预后信息，评估SLC25A12表达在两个独立的AML研究队列（分别为n = 163和n = 329）中的预后价值。
AML患者中SLC25A12的表达与健康人相比显著升高（P分别为0.0001和0.0238）。单因素和多因素分析显示，SLC25A12高表达与患者较短的无事件生存期（EFS）（HR = 1.605，P = 0.018）和总生存期（OS）（HR = 1.818，P = 0.002）显著相关。在低危和中危亚组中，SLC25A12高表达的患者比SLC25A12低表达的患者EFS和OS更短。
SLC25A12高表达与AML患者的不良预后显著相关，这表明SLC25A12异常表达可作为评估AML患者预后的潜在分子标志物。
